艾力斯前三季度净利16.16亿元，同比增长52.01%

Group 1 - The core viewpoint of the article highlights that Ailis (688578) reported significant growth in both revenue and net profit for the first three quarters of 2025, with revenue reaching 3.733 billion yuan, a year-on-year increase of 47.35%, and net profit attributable to shareholders amounting to 1.616 billion yuan, up 52.01% [1] - The sales of the company's core product, Fumetinin tablets, have been increasing steadily, contributing to the notable revenue growth during the reporting period [1] - The company has managed to control costs and expenses effectively, ensuring that profit totals, net profit attributable to shareholders excluding non-recurring gains and losses, and earnings per share have all experienced rapid growth in tandem with revenue [1]